Nilotinib
- OralNilotinibTasignaBinds both active & inactive conformation of Bcr-Abl kinase, resulting in reduced resistance
Mechanism of Action
- Inhibits the Bcr-Abl tyrosine kinase as well as the stem cell receptor factor (cKIT) and several other receptor tyrosine kinases.
Clinical Use
Indications
- Philadelphia chromosome positive chronic myeloid leukaemia in the chronic phase or with resistance or intolerance to imatinib
- Adverse Effects
- Rash
- Fatigue
- Oedema
- Nausea / vomiting / diarrhoea
- Muscle cramping
- Peripheral neuropathy
- LFT derangement
- Myelosuppression - anaemia, neutropaenia, thrombocytopaenia
- Cardiovascular - cardiac ischaemia, stroke, peripheral vascular disease, hypercholesterolaemia